Amendments to the Claims:

This listing of claims will replace all prior versions and listings of claims in the application:

Listing of Claims:

1(Currently amended). A <u>isolated</u> peptide consisting of:

- (a) 9 or 10 contiguous amino acid residues that appear in the sequence of <a href="https://www.human.com/h
- (b) a non-natural modification of (a) to form a modified peptide that promotes effective binding to a MHC class 1 type molecule so as to elicit a CTL response.

Claims 2-15 (Cancelled).

16(Currently amended). [[A]] An isolated peptide selected from the group consisting of SEQ ID NOs: 35, 36, 37, 38, 39, 40, and 41.

Claims 17-18 (Cancelled).

19(Currently amended). The <u>isolated</u> peptide of claim 1, wherein said <u>isolated</u> peptide is derived from a mammal <u>a peptide</u> (a) <u>from human Lactadherin (BA-46)</u>.

Claim 20 (Cancelled).

21(Currently amended). The <u>isolated</u> peptide of claim 1, wherein said peptide includes at least one non-natural modification.

Claim 22 (Cancelled).

Appln. No. 09/744,804 Amdt. dated May 17, 2004 Reply to Office Action of February 20, 2004

23(Currently amended). The <u>isolated</u> peptide of claim 21, wherein said at least one modification is selected from the group consisting of peptoid modification, cyclic peptide modification, N terminus modification, C terminus modification, peptide bond modification, backbone modification and residue modification.

Claims 24-43 (Cancelled).

44 (Currently amended). The <u>isolated</u> peptide of claim 1, wherein the second residue and the end residue are neutral, hydrophobic and aliphatic.

Claim 45-54 (Cancelled).

55(Currently amended). The <u>isolated</u> peptide according to claim 16, consisting of SEQ ID NO:38.

56(Currently amended). The <u>isolated</u> peptide according to claim 16, consisting of SEQ ID NO:39.

\$ 57(Currently amended). The <u>isolated</u> peptide according to claim 16, consisting of SEQ ID NO:41.

58 (Currently amended). [[The]] An isolated peptide of claim 1, consisting of 9 or 10 contiguous amino acid residues that appear in the sequence of Lactadherin (BA-46), which isolated peptide promotes effective binding to a MHC class 1 type molecule so as to elicit a CTL response.